logo
Twitter
Discord
Email
logo
Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.

NASDAQ•GLSI
CEO: Mr. Snehal S. Patel
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-09-25
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Contact Information
Building 14, 3992 Bluebonnet Drive, Stafford, TX, 77477, United States
832-819-3232
greenwichlifesciences.com
Market Cap
$344.43M
P/E (TTM)
-17.4
38.2
Dividend Yield
--
52W High
$32.91
52W Low
$7.78
52W Range
68%
Rank52Top 73.5%
2.9
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.30+50.00%
4-Quarter Trend

FCF

-$2.67M+3.38%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Financing Inflow Net cash from financing activities totaled $6.45M for nine months 2025, driven by ATM sales exceeding $6.30M in proceeds.
R&D Spending Rises Research and development expenses grew 42% to $9.63M for nine months 2025, reflecting increased clinical trial costs and option grants.
Warrant Exercise Completed Remaining underwriter warrants exercised in September 2025, providing $145K gross proceeds to support ongoing operations and liquidity.

Risk Factors

Net Loss Widening Nine month net loss reached $(11.44M) in 2025, a substantial deterioration from $(7.75M) loss reported in the prior year period.
Going Concern Uncertainty Management notes substantial doubt regarding ability to continue as going concern due to cumulative net losses and negative operating cash flows.
Internal Control Weakness Material weaknesses found in internal controls due to inadequate segregation of duties and limited personnel noted as of September 30, 2025.

Outlook

Additional Capital Required Expect continued net losses and require additional capital raises through equity or debt to meet long-term operating requirements going forward.
Clinical Trial Expansion Expanding Phase III Flamingo-01 trial into Europe, planning to open up to 150 sites globally for GLSI-100 evaluation efficacy and safety.
Increased Operating Costs Expect significant expenses to build infrastructure for expanded operations, clinical trials, and future commercialization functions like manufacturing.

Peer Comparison

Revenue (TTM)

C4 Therapeutics, Inc.CCCC
$30.11M
-10.6%
Nuvectis Pharma, Inc.NVCT
$26.80M
-753.4%
PepGen Inc.PEPG
$1.49M
-10.1%

Gross Margin (Latest Quarter)

C4 Therapeutics, Inc.CCCC
100.0%
+13.4pp
Cardiff Oncology, Inc.CRDF
100.0%
+0.0pp
Anixa Biosciences, Inc.ANIX
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CYBN$413.02M-2.6-51.8%15.9%
PEPG$357.49M-1.8-84.1%9.2%
GLSI$344.43M-17.4-1042.8%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Apr 21, 2026
|
EPS:-$0.32
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.30+50.0%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.30+50.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 20, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.25+31.6%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 15, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.21-75.4%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.20+5.3%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.20+53.8%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 20, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.19+18.8%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 15, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.69-13.1%
    N/A